Author: admin

  • Hydroxychloroquine Effective for Proteinuria Reduction in Primary Glomerular Disease

    Hydroxychloroquine Effective for Proteinuria Reduction in Primary Glomerular Disease

    New research is shedding light on the potential benefits of hydroxychloroquine for the treatment of primary glomerular diseases, highlighting its impact on proteinuria reduction but lack of improvement in overall estimated glomerular filtration rate (eGFR).1

    The systematic review and meta-analysis included 13 studies assessing oral hydroxychloroquine in adult patients with primary glomerular disease and found that while it was effective in reducing proteinuria levels irrespective of disease type and treatment duration, improvement in eGFR was limited to patients with IgA nephropathy.1

    Glomerular disease often progresses slowly, presenting with no symptoms for many years but eventually causing serious health problems, including high blood pressure, nephrotic syndrome, chronic kidney disease, and kidney failure. It is a prominent cause of renal impairment, leading to 10-15% of end-stage renal disease cases in the United States, and is primarily treated with immunosuppressive agents linked to serious long-term side effects and loss of efficacy over time, highlighting the need for alternative therapies to improve outcomes and minimize the associated adverse effects in this patient population.2,3

    “Most available studies have focused on hydroxychloroquine’s role in secondary glomerular diseases, such as lupus nephritis, leaving its potential for primary glomerular diseases underexplored. Furthermore, there is a lack of data on how hydroxychloroquine’s effects vary based on disease subtypes, patient demographics, and treatment duration,” Gerry Mathew, an associate professor of nephrology at SRM University in India, and colleagues wrote.1 “Addressing these gaps is critical for evaluating hydroxychloroquine as a viable therapeutic alternative for primary glomerular diseases and for reducing the dependency on traditional immunosuppressive therapies with high side-effect profiles.”

    To assess the safety and efficacy of hydroxychloroquine in primary glomerular diseases, investigators conducted a literature search across PubMed, ScienceDirect, Wiley Online Library, Springer, and Google Scholar for studies meeting the following inclusion criteria:

    • Involving patients diagnosed with primary glomerular disease
    • Incorporating hydroxychloroquine as a part of the treatment regimen for affected patients with doses ranging from to 200–400 mg or 5 mg/kg body weight
    • Primary glomerular diseases considered for the study, including minimal change disease, focal segmental glomerulosclerosis, membranous nephropathy, IgA nephropathy, and idiopathic membranoproliferative glomerulonephritis
    • Publications available in English
    • Published in peer-reviewed journals between 2014 and 2024

    A total of 13 full-text articles satisfied all the eligibility criteria and were included in the meta-analysis. Investigators noted most of the studies (n = 12) were conducted in China but demonstrated heterogeneity in study design, population demographics, and baseline characteristics.1

    Among the 8 studies reporting 24 hour urinary protein levels in patients at the end of hydroxychloroquine treatment, pooled analysis revealed a significant reduction in proteinuria in 1010 patients (MD, -0.69; 95% CI, -0.79 to -0.59; P <.00001), with moderate heterogeneity observed across the included studies (I2 = 85.6%; P = .008). Subgroup analysis showed a significant difference in proteinuria decrease in patients treated with hydroxychloroquine for both short-term (MD, -0.49; 95% CI, -0.66 to -0.32; P <.00001) and long-term (MD, -0.74; 95% CI, -0.81 to -0.67; P <.00001) durations compared to baseline levels.1

    A total of 13 studies compared the effects of hydroxychloroquine treatment on proteinuria levels in 1161 patients with IgA nephropathy and membranous nephropathy. Subgroup analysis revealed a significant reduction in the measured parameters for 797 patients with IgA nephropathy following treatment (MD, -0.67; 95% CI, -0.74 to -0.60; P <.00001), with low heterogeneity across studies (I2 = 24%). Of note, there was a more substantial reduction in the parameter for 364 patients with membranous nephropathy compared to IgA nephropathy (MD, -3.00; 95% CI, -4.46 to -1.53; P <.0001), but with high heterogeneity (I² = 98%) suggesting that the results vary considerably across studies.1

    Further analysis revealed no significant improvement in eGFR after hydroxychloroquine treatment (MD, -1.03; 95% CI, -2.73 to − 0.67), with findings consistent regardless of treatment duration. However, a beneficial effect was observed in patients with IgA nephropathy (MD, -2.65; 95% CI, -5.16 to -0.14).1

    Among the included studies, a total of 69 adverse events were reported. Gastrointestinal and mucocutaneous effects, each accounting for 20 cases, were the most commonly reported adverse events, representing approximately 58% of the total adverse events.1

    “This comprehensive assessment aids in understanding the therapeutic potential and risk profile of HCQ in primary glomerular diseases and identifying gaps in current knowledge to guide future research directions,” investigators concluded.1

    References

    1. Mathew GG, Sundaramurthy S, Muthuperumal P, Jayaprakash V. Role of hydroxychloroquine in primary glomerular disease – a systematic review and meta-analysis of the current evidence. BMC Nephrol. 2025 doi:10.1186/s12882-025-04370-2
    2. National Institutes of Health. Glomerular Disease. June 2022. Accessed August 18 2025. https://www.niddk.nih.gov/health-information/kidney-disease/glomerular-disease
    3. Kazi AM, Hashmi MF. Glomerulonephritis. StatPearls. June 26, 2023. Accessed August 18 2025. https://www.ncbi.nlm.nih.gov/books/NBK560644/

    Continue Reading

  • Two Carnival cruise guests drown at new Bahamas resort on same day | Carnival

    Two Carnival cruise guests drown at new Bahamas resort on same day | Carnival

    Two US nationals in their 70s apparently drowned in two separate incidents on Friday at a new resort in the Bahamas, according to officials.

    The deaths happened at Celebration Key, a $600m private destination created for Carnival Cruise Line passengers that launched in July about 100 miles (160km) off the coast of Florida.

    “Our lifeguards and medical team responded to two separate emergency incidents at Celebration Key on Friday,” one of which was in a lagoon and the other of which was on a beach, Carnival Cruise Line said in a statement reported by ABC News. “Sadly, both guests have passed away.”

    Authorities reported that the first death occurred shortly before noon. A 79-year-old man snorkeling off the beach was discovered unresponsive.

    A lifeguard pulled him to shore and tried resuscitation efforts, but he was later declared dead by medical doctors, according to a police statement.

    The second drowning happened roughly two and a half hours later. A 74-year-old woman was found unconscious while swimming in a pool.

    A lifeguard performed CPR after removing her from the water, and she, too, was pronounced dead.

    Police said autopsies would be conducted to determine the pair’s exact causes of death, with investigations still ongoing into both. The victims’ names have not been released.

    Carnival confirmed to Nexstar that the two guests had been traveling separately with their families onboard different ships: the Carnival Mardi Gras, which departs from Port Canaveral in Orlando; and the Carnival Elation, which sails from Jacksonville.

    “Our thoughts and prayers are with the guests and their families, and our care team is providing assistance,” the statement from the cruise line said.

    The company said it was working with law enforcement as the investigation proceeds.

    Besides beaches and lagoons, Celebration Key’s various zones include pools, a swing bar and retail areas. Carnival projects about 2 million visitors will pass through annually, with that number expected to double by 2028.

    Continue Reading

  • Fly me to the moon: 25 finalists chosen for Artemis 2 ‘zero-g indicator’

    Fly me to the moon: 25 finalists chosen for Artemis 2 ‘zero-g indicator’

    When the Artemis 2 astronauts launch to the moon next year, they will be accompanied by one of 25 plush toys just named a finalist in a NASA contest.

    The space agency and Freelancer, a crowdsourcing company, on Friday (Aug. 15) announced the winners of the “Moon Mascot: NASA Artemis II ZGI Design Challenge,” which ran from March through June. NASA will now select from the finalists a single doll to become the mission’s zero-gravity indicator (ZGI).

    The designs range from anthropomorphized animals, mythological creatures and nods to NASA’s past, present and future space exploration efforts. A full list of the winners along with their submissions can be viewed at collectSPACE.com.

    The 13 finalist entries submitted by adults in the “Moon Mascot: NASA Artemis II ZGI Design Challenge.” (Image credit: NASA/Freelancer/collectSPACE.com)

    “These finalists have proven they indeed have ‘the right stuff,’” said Matt Barrie, Freelancer chief executive, in a statement.

    Continue Reading

  • Exclusive: Egypt agrees to buy at least 200,000 tons of French wheat, state buyer says – Reuters

    1. Exclusive: Egypt agrees to buy at least 200,000 tons of French wheat, state buyer says  Reuters
    2. French wheat is loaded aboard the “Sammy” in the port of Dunkirk and will transport 63,000 tons to Egypt  Reuters Connect
    3. Egypt agrees to buy at least 200,000 tons of French wheat, state buyer says  TradingView
    4. Egypt Procures Nearly 4 Million Tons of Wheat this Season  Asharq Al-awsat – English

    Continue Reading

  • Jacob Ramsey: Newcastle and Aston Villa fans unite against PSR

    Jacob Ramsey: Newcastle and Aston Villa fans unite against PSR

    Aston Villa’s loss is Newcastle’s gain.

    Following three quiet windows, Newcastle have been able to reinforce their squad after substantial deficits dropped out of the club’s three-year PSR cycle, which takes the financial years ending 2024, 2025 and 2026 into account.

    Newcastle have seen several targets move elsewhere, and the Alexander Isak saga continues to hang over the club, but the black-and-whites have brought in Anthony Elanga, Malick Thiaw, Aaron Ramsdale and, now, Ramsey, who is a player Howe “loved” from afar.

    Ramsey certainly looks like a Howe player and the versatile midfielder was even ranked second for possessions won (15) in the final third for Aston Villa in the top-flight last season.

    Newcastle may be well-stocked in the middle of the park, but the 24-year-old’s athleticism, ball-carrying ability and experience in the Premier League and Champions League will be invaluable as the club prepare to fight on four fronts.

    There are clear areas for improvement, too.

    Ramsey registered just six goal involvements in the top-flight last season, but Callum Rowe recalled how his friend “always had an eye for scoring” after the pair came through the ranks together at Aston Villa.

    “He has the natural ability for arriving in the box from midfield and scoring goals, which, in my opinion, is something you can’t teach,” he said.

    A chance to work on these aspects of his game under Howe was certainly a big draw for Ramsey.

    Anthony Gordon, Dan Burn, Lewis Hall and Tino Livramento have all become senior England internationals following an extended period with the Newcastle head coach and his staff.

    And Ramsey, who previously won the European Championships with England Under-21s, hopes to one day follow suit.

    It does not feel unrealistic if Ramsey can continue to keep himself fit following an injury-disrupted 2023-24.

    Smith, for one, has no doubt that there is “more to come” from the midfielder, who is “very coachable”.

    “Eddie is really good with the players so Jacob will settle in with him really well,” the former Aston Villa manager said. “He could thrive under him and I can see why Eddie has gone for him. He’s his type of player. He fits in with the work ethic. He’s got the skillset.

    “With my Villa head on, I’d rather see him at Villa still, but he’s going to a Champions League team and a big, well-supported club so I wish him well. He will handle it.”

    Continue Reading

  • Early Release – Sporothrix brasiliensis Treatment Failure without Initial Elevated Itraconazole MICs in Felids at Border of Brazil – Volume 31, Number 9—September 2025 – Emerging Infectious Diseases journal

    Early Release – Sporothrix brasiliensis Treatment Failure without Initial Elevated Itraconazole MICs in Felids at Border of Brazil – Volume 31, Number 9—September 2025 – Emerging Infectious Diseases journal

    Sporotrichosis is a globally neglected epizoonotic and sapronotic disease, primarily affecting the skin and subcutaneous tissues, caused by fungi of the Sporothrix genus, and represents the most prevalent implantation mycosis in Latin America, especially in Brazil (1). Sporothrix spp. are thermally dimorphic fungi from the order Ophiostomatales, showing filamentous forms at 25°C–30°C in the environment and yeast-like forms at temperatures of 35°C–37°C, as in mammals (2). The main clinical pathogenic species are S. brasiliensis, S. schenckii, S. globosa, and S. luriei. S. schenckii and S. globosa are usually transmitted via the sapronotic route, involving traumatic implantation with plant or soil debris (3). During the past 3 decades, zoonotic transmission of S. brasiliensis from infected cats to humans, other felids, and canines has resulted in multiple outbreaks in Brazil and other Latin America countries (47). Cat-transmitted sporotrichosis caused by S. brasiliensis is a major public health concern in Latin America. Infections are rapidly spreading from Brazil to other countries, and cases have been described in Brazil (8,9), Argentina (5,10), Paraguay (4), and Chile (6). In addition, imported cases in the United Kingdom (11) and United States (12) have been reported. Transmission by infected cats, via yeast form (13), occurs through bites, scratches, direct contact with exudate from skin lesions, and probably through respiratory droplets by cat sneezes (2,14). Cats are the primary animal hosts and main source of infection for other cats, dogs, and humans (15).

    Cat-transmitted sporotrichosis outbreaks often involve clonal zoonotic transmission (8,16). To curb such outbreaks, one of the necessary measures is antifungal treatment of cats (15). The drug of choice is itraconazole, although various refractory cases have been reported (17,18). Whether treatment failure results from high antifungal MICs is unknown because that possibility has been poorly investigated (19). Recently, high antifungal MICs against itraconazole were reported in isolates obtained from both cats and humans (1921). Whether strains with reduced susceptibility are also transmitted or whether reduced susceptibility only develops during treatment remain unclear. Antifungal susceptibility testing (AFST), applicable to both the yeast and mycelial form, has not been standardized in dimorphic fungi, leading to different protocols. As a consequence, published MICs are currently difficult to compare.

    We investigated the spread of feline sporotrichosis in the triple border region between Brazil, Paraguay, and Argentina by molecular genotyping. In addition, we obtained MICs for common antifungal drugs using microbroth dilution methods of both the yeast and mycelial phase to determine whether cats with sporotrichosis had S. brasiliensis with elevated itraconazole MICs at the onset of treatment. This study was approved by the Committee for Ethics in Research of the Federal University of Paraná (approval no. CAAE 52726021.8.0000.0102) and by the Animal Use Ethics Committee of the Federal University of Paraná, Curitiba, Brazil.

    Isolate and Data Collection

    During July 2021–October 2023, we collected swab samples from 108 symptomatic cats that had lesions compatible with sporotrichosis. All cats lived in the triple border region between Brazil, Paraguay, and Argentina. Cats were selected through notification of the owners; health agents of the Zoonosis Control Center of Foz do Iguaçu, Brazil; veterinarians from private clinics and hospitals; and receipt at the Zoonosis Control Center of animals suspected to be infected. In Foz do Iguaçu, samples were collected at the homes of the cats or at the place indicated by the citizen in cases of stray cats. In Paraguay, samples were collected at private veterinary clinics. We obtained clinical and environmental data by using questionnaires sent to the owners of each cat.

    We evaluated and classified all cats according to the types of their lesions and divided them into 3 groups: cutaneous disseminated, cats with ulcerated lesions in different parts of the body and systemic signs; fixed cutaneous, cats with single ulcerated lesion without systemic signs; and extracutaneous, cats without ulcerated lesions but with other clinical manifestations including sneezing, dyspnea, nasal discharge and other respiratory symptoms. We used cartographic bases from the Brazilian Institute of Geography and Statistics (IBGE) for georeferencing the coordinates where cats lived and QGIS software (https://qgis.org) to assemble the maps. To determine clinical outcomes, we followed the cats for the duration of treatment, until they died, recovered, or were lost to follow-up.

    Diagnosis and Molecular Investigation

    We diagnosed sporotrichosis via fungal culture of swab specimens collected from the wounds, as previously described (4). We cultivated specimens on Sabouraud dextrose agar (KASVI, https://www.kasvi.com.br) containing chloramphenicol and incubated at 25°C–27°C for up to 10 days. We performed micromorphology of colonies to confirm Sporothrix growth and calmodulin sequencing for species identification, as previously described (4). As control isolates, we used S. brasiliensis CBS 133017 (GenBank accession no. KP101458.1), S. schenckii CBS 117440 (accession no. KP101386.1), S. globosa CBS 129721 (accession no. KP101478.1), S. luriei ATCC 18616 (accession no. KT427639.1), S. mexicana Ss133 (accession no. JF811341.1), S. chilensis Ss470 (accession no. KP711816.1), S. humicola CBS 118129 (accession no. KX590808.1), and S. phasma CBS 119721 (accession no. KX590795.1). We deposited sequences generated in this study into GenBank (accession nos. OR501574, OR501573, and PQ741608–713) (Appendix Table 1). We performed genotyping of isolates using short tandem repeats, as previously described (16) (Appendix).

    AFST

    We performed AFST for the mycelial and yeast phases of all isolates using broth microdilution as outlined in Clinical and Laboratory Standards Institute (CLSI) reference standard M38 for the mycelial phase (22,23) and CLSI reference standard M27 for the yeast phase (24) (Appendix). For the mycelial phase, we cultured isolates on potato dextrose agar (Sigma Aldrich, https://www.sigmaaldrich.com) plates at 30°C for 7 days and confirmed the absence of yeast cells microscopically. For the yeast phase, we cultured isolates onto brain–heart infusion plates (Xebios Diagnostics GmbH, https://www.xebios.com) at 35°C for 7 days, then performed a second passage on brain–heart infusion plates at 35°C for 7 days. We then microscopically confirmed the absence of filamentous fungi.

    Clinical Epidemiology

    Figure 1

    Figure 1. Heatmaps showing the spatial distribution of cats with proven sporotrichosis in the triple border region of Brazil (white), Paraguay (dark gray), and Argentina (light gray) during 2021–2023 in study of …

    We obtained 108 isolates of Sporothrix spp. originating from 88 households (Appendix Table 1). Of the animals, 100 were from Foz do Iguaçu (Brazil), 4 from Ciudad del Este (Paraguay), and 4 from Hernandarias (Paraguay). No animals had a history of travel to other regions. Sporotrichosis cases were initially only found in neighborhoods in the eastern region of Foz do Iguaçu (Figure 1, panel A), but over time, cases were found in other regions, close to the country border, especially around the international bridges (Figure 1, panels B, C). The prevalence of sporotrichosis cases was highest in the northern, southern, and eastern districts (Table 1), regions with the highest density of humans (Appendix Figure 1). Furthermore, most cases were found at or close to low-income urban communities and favelas (Appendix Figure 2), which are low-income, dense housing settlements, characterized by low socioeconomic status, precarious conditions, and lack of essential services, mostly found at the eastern region of Foz do Iguaçu (Appendix Figure 2). Of note, all cats had easy access to the street, other homes, backyards, and vacant lots. Feline sporotrichosis was more frequently in male cats (male:female ratio 2.8:1), adults, uncastrated cats, those not vaccinated for any disease, and those with little or no access to veterinary services; most cats did have an owner (Table 2).

    The main clinical manifestation was cutaneous disseminated sporotrichosis (61%), followed by fixed cutaneous (34%) and extracutaneous (5%) sporotrichosis (Table 3). The mortality rate was 61% for cats with the disseminated form, but no cats with the fixed cutaneous or extracutaneous forms died from sporotrichosis. Ten animals were euthanized because they lived on the street without owners, hindering any possibility of treatment; 8 cats were lost to follow-up.

    All cats received itraconazole (25–100 mg/d), and those with disseminated and extracutaneous forms also received potassium iodide (2.5–20 mg/kg/24 h, depending on the severity of symptoms). For the clinically cured cats, treatment duration ranged from 2 to 15 months, and we observed no correlation to the clinical form (Table 4). For the cats that died, 12 never received treatment; for the others, treatment duration ranged from 1 week to 7 months.

    Phylogenetic Analysis

    Figure 2

    Minimum-spanning tree of isolates in study of Sporothrix brasiliensis treatment failure without initial elevated itraconazole MICs in felids at border of Brazil. Tree comprises 283 isolates, including 108 isolates based on 9 short tandem repeat markers from this study (red and yellow); green, blue, and pink indicate comparison isolates from previous studies; and numbers in the key represent the number of isolates from each location. Gray dashed circle indicates Rio de Janeiro clade. Regions of Brazil: south, Paraná, Rio Grande do Sul; southeast, Rio de Janeiro, Minas Gerais, São Paulo, Espírito Santo; central-west, Federal District.

    Figure 2. Minimum-spanning tree of isolates in study of Sporothrix brasiliensistreatment failure without initial elevated itraconazole MICs in felids at border of Brazil. Tree comprises 283 isolates, including 108 isolates…

    Calmodulin sequencing identified all 104 isolates as S. brasiliensis, displaying no genetic variation within that gene. Short tandem repeat genotyping yielded 20 genotypes, of which 6 previously had been found in other regions (16) (Figure 2). All isolates from the triple border region were highly related, and all grouped within the Rio de Janeiro clade, a previously described dominant group of genotypes originating from Rio de Janeiro, Brazil (16). In this study, those isolates often clustered with isolates from other regions of Paraná, Rio de Janeiro, and several other states. In addition, isolates did not cluster based on clinical outcome; all clusters contained isolates from cats who were clinically cured, died, and were euthanized (Appendix Figure 3).

    MIC Investigation

    Figure 3

    Distribution of MICs for 108 clinical isolates in study of Sporothrix brasiliensis treatment failure without initial elevated itraconazole MICs in felids at border of Brazil. MICs were determined according to Clinical Laboratory and Standards Institute M38 (22) and M27 (24) guidelines. Red dotted lines indicate division of wild-type versus non–wild-type isolates based on ECV values proposed by Espinel-Ingroff (23), when available. The ECV value for voriconazole is 32 µg/mL. MICs are given in µg/mL. For AFG and MFG, the MEC50 (filamentous phase) was determined. AFG, anidulafungin; AMB, amphotericin B; FLU, fluconazole; ISA, isavuconazole; ITC, itraconazole; M, mycelial phase; MEC50, minimal effective concentration that inhibits 50% of isolates; MFG, micafungin; MIC50, MIC that inhibits 50% of isolates; POS, posaconazole; TRB, terbinafine; VOR, voriconazole; Y, yeast phase.

    Figure 3. Distribution of MICs for 108 clinical isolates in study of Sporothrix brasiliensistreatment failure without initial elevated itraconazole MICs in felids at border of Brazil. MICs were determined according…

    For AFST, on the basis of Espinel-Ingroff et al. (23), who proposed epidemiological cutoff values (ECVs) based on the M38 CLSI protocol (22), we classified all isolates as wild-type for antifungal drugs with available ECVs (Figure 3). For the mycelial phase, itraconazole and posaconazole had the highest in vitro activity, followed by amphotericin B. In contrast, fluconazole, voriconazole, and isavuconazole had low activity and high MICs. For the yeast phase, itraconazole, posaconazole, and isavuconazole showed the highest activity, followed by voriconazole and amphotericin B. Comparing susceptibility levels between both phases, isolates at the mycelial phase had higher MICs for all azoles (for example, differences in 50% MIC values were 8-fold for itraconazole, 64-fold for voriconazole, and 128-fold isavuconazole) and amphotericin B, whereas terbinafine and echinocandins had higher MICs at the yeast phase. Finally, the geometric mean of strains isolated from cats with disseminated disease that recovered was similar to those from cats that died (Appendix Table 2).

    Epidemiologic data show that, within 3 years, S. brasiliensis–induced sporotrichosis spread across the triple border region of Brazil, Paraguay, and Argentina. The rapidly increasing number of cases in felids highlights the severity of sporotrichosis as a public health problem and the potential for outbreaks (25). The data also suggest that cat-transmitted sporotrichosis mainly affects an urban cat population in areas with a high concentration of humans and likely also cats, as compared with areas with a low density of humans (8,26). All cats in this study were free to roam outside with access to the street, other homes, backyards, and vacant lots, and although no cats had reported travel history, they were also able to roam freely across national borders in this region. We observed introduction of sporotrichosis into Paraguay near the international bridges in the area. Furthermore, based on general assumptions, cases correlate with low socioeconomic status; the eastern region of Foz do Iguaçu has a low overall standard of living. As a consequence, most cats had owners but no access to a veterinarian (27). In most cases, owners were not financially able to provide basic resources for their cats’ health and, in cases of sporotrichosis, they were not able to provide diagnosis and treatment. Therefore, public policies that provide such tools free of charge are crucial.

    Although all reported sporotrichosis cases in both the Brazil and Paraguay sides of the border were included, most isolates originated from Brazil. The population numbers for the cities at the triple border region are similar; the 2024 population of Foz do Iguaçu was 295,000 (28) and of Ciudad del Este was 339,000 (29). The numbers for the feline populations are not known for either city. The differences in sporotrichosis cases are partly the result of the river between the 2 countries, which halted spread originating from the east of Brazil. In addition, differences between the healthcare systems of the 2 countries might play a role. In Brazil, the Health Unic System (SUS) is a decentralized system, meaning that the city decides how the resources from the state and the federal government will be used (30). In Paraguay, a centralized health system has most action concentrated in the capital, Asunción, which is 324 km from the border (30). Although the Epidemiologic Laboratory in Ciudad del Este can track cases and diagnose sporotrichosis in cats and humans free of charge, not enough clinicians and veterinarians are available.

    In this study, uncastrated and unvaccinated male cats represented most patients with feline sporotrichosis, as previously described (31). Unvaccinated cats may have comorbidities such as feline leukemia virus, calicivirus, herpes, and panleukopenia, leading to immunosuppression and rapid evolution to the disseminated form of sporotrichosis (32). Castration of male cats reduces production of testosterone and curbs behaviors of territory disputes and sexual intercourse between male and female cats, both of which usually involves fights with injuries, so reducing those interactions decreases chances of transmission to female cats and newborn kittens (33). Because most cats in this study were >12 months of age, public interventions (vaccination and neutering programs) at <12 months of age would likely reduce the risk for transmission of sporotrichosis. Such measures are crucial to control and prevent sporotrichosis based on a One Health approach, which also reinforces the need for public health education, especially about responsible cat ownership. Furthermore, the lack of awareness about this disease among health professionals is a primary difficulty in identifying sporotrichosis in humans and animals, making searching for cases more difficult (12). Thus, public health education on responsible feline ownership and increasing disease awareness in health professionals are the first steps toward preventing sporotrichosis outbreaks and providing effective treatment (34).

    To show the genetic relatedness among the S. brasiliensis isolates, we performed short tandem repeat analysis (35). All isolates clustered in the Rio de Janeiro clade and were closely related to isolates from the south and southeastern parts of Brazil. Curitiba and other cities in the Brazil state of Paraná have steadily reported S. brasiliensis cases since 2011, and those isolates display identical or highly related genotypes (16). The introduction of S. brasiliensis in regions could happen by the movement of sick or colonized cats (11). The isolates from this study were closely related to those from Curitiba, which, like Foz do Iguaçu, is in Paraná state, although the 2 regions are >600 km apart. Even though all our isolates clustered in the Rio de Janeiro clade (16), we identified different genotypes, so multiple introductions cannot be excluded. Whole-genome sequencing is needed to elucidate the origin of S. brasiliensis in this region and whether all isolates originate from the same strain. Finally, we observed different clinical manifestations and mortality rates, but those differences were not related to different genetic backgrounds of isolates.

    We determined MIC values for 9 different antifungal drugs for S. brasiliensis isolates in both the pure yeast and mycelial phases and microscopically confirmed results. According to the interpretation of an international multicenter study for definition of tentative ECVs for mycelial S. brasiliensis (23), all isolates were susceptible to amphotericin B, itraconazole, voriconazole, posaconazole, and terbinafine (36). Espinel-Ingroff et al. used standard incubation of 2–3 days at 35°C, according to the CLSI reference standard M38 for filamentous fungi, whereas in our study, we used 30°C to avoid conversion of the mold form. We found that incubation at 35°C induces transition to the yeast phase, taking up to 2 weeks for full transition. Because Espinel-Ingroff et al. did not perform microscopy, the ECVs possibly were established on a mixture of filamentous and yeast phases in that study. Moreover, many centers were excluded because of insufficient or unsuitable data, suggesting suboptimal methodology or implementation (23). Thus, additional studies are required to analyze the impact of yeast–mold mixtures resulting from short incubation at 35°C versus pure mold at 30°C on the MICs and to establish the ECVs. Nonetheless, the normal distribution of our MIC values indeed suggests an absence of non–wild-type isolates. Of note, we found mycelial phase MICs were overall higher than those for the yeast phase. One explanation for that difference is the higher concentration of melanin in the cell wall in the filamentous phase. Melanin is associated with a reduced susceptibility to antifungal drugs. However, it is important to note that MICs for most of the drugs in the mycelial phase were read at 100% inhibition compared with growth control, whereas at the yeast phase, inhibition was 50%. Therefore, direct comparisons of the MICs between both phases should be made with caution.

    AFST results might not reflect in vivo treatment in the absence of clinical breakpoints (34). Nonetheless, for itraconazole, which is the first-choice drug for feline treatment (15,34), MICs of all isolates in both phases were below the tentative ECV, and similar results were reported earlier (17,37). In contrast, other studies recently found MICs of itraconazole and other azoles above the tentative ECV (19,38). Of note, the reported bimodal distribution with low and elevated MICs for itraconazole, and the identification of cyp51 mutants (19) suggests that those MICs would also be well above the tentative ECV in conditions of pure mycelial and yeast phase (23). That discrepancy with our study might be because we included different strains. Our collection consisted of closely related genotypes only, and strains were isolated before start of treatment. Smaller MIC differences could also be explained by differences in AFST protocols, including the mixed presence of filamentous and yeast phases. Other factors, including panel preparation, media or reagents, and inoculum preparation, might influence AFST results. Finally, because the mycelial form had the least variation in our genotypically similar isolates, is easiest to use, and mycelial AFST data seemingly correspond to in vivo failure of voriconazole (39), the mycelial phase might be most suitable for AFST. A multicenter evaluation comparing robust AFST methodologies in a genotypically variable cohort would be needed to establish the best method to determine antifungal susceptibility for S. brasiliensis. Moreover, further research is needed to determine whether inoculum incubation at 35°C, in adherence with the M38 guideline for the mycelial phase, has influence on MIC outcome in comparison to incubation at 30°C.

    We observed a high (61%) mortality rate in cats with the disseminated form and no sporothrichosis-related deaths in cats with the fixed cutaneous form. Other studies reported unfavorable clinical outcomes in 32%–59% of cats with the disseminated form (4042). In our study, all cats with extracutaneous form achieved clinical cure, in contrast with previous studies, which generally considered that form to be indicative of a poor prognosis and high chances of treatment failure and death (15,41). Of note, all isolates in our study were genetically similar and displayed initially low MICs of itraconazole, used for sporothrichosis treatment in all cats. The 50% MIC levels of strains isolated from cats with the disseminated form that were cured were also not different from those that were not cured. Thus, the mortality rate in cats with the disseminated form is not because of initial elevated MICs, although we cannot exclude the development of reduced susceptibility overtime because we did not collect isolates after itraconazole treatment. The observation that transmission only involved itraconazole-susceptible isolates, because we did not find an isolate with high MIC in any cat, suggests that an increase in MICs was probably uncommon, if present at all. Moreover, some cats from the same household became infected months after each other, and in those households no elevated MICs were found, suggesting no resistance was acquired within the households despite itraconazole exposure. However, isolates collected after itraconazole exposure should be tested to formally exclude resistance development. Regarding treatment failure, other factors, such as disease progression, treatment variations, and host factors, likely were involved in treatment failure in this cohort. Besides clinical outcomes, treatment duration was different between clinical forms. Cats with the fixed cutaneous form were treated for fewer months. Disease progression is likely to play an important role, but erratic itraconazole pharmacokinetics might also be involved.

    For feline sporotrichosis, the proposed itraconazole dose by the guideline for the management of feline sporotrichosis caused by S. brasiliensis is 100 mg/24 hours for cats >3 kg (15). To our knowledge, however, a robust dose-response study evaluating the efficacy of that dose is lacking. When administering the medication, guidelines recommend opening the capsules over a small amount of wet food (15); however, no studies have verified the absorption degree of itraconazole administered that way. In disseminated cases, whether itraconazole can reach the mucous membranes at an adequate level for cure also is unknown. Moreover, the disease in the disseminated form could be too advanced to treat with itraconazole. However, suboptimal itraconazole blood levels prolong treatment and increase risk for resistance development in other diseases (43,44). Optimal dosing to reach effective serum itraconazole concentrations in severe disease would enable the best standard of care, but that information is not available for cats. Alternative therapeutic strategies should be investigated for the disseminated feline form to reduce mortality.

    In summary, our investigation of cat-transmitted sporotrichosis caused by S. brasiliensis at the triple border region of Brazil, Paraguay, and Argentina found that varying clinical manifestations of sporotrichosis and large differences in mortality rates were not caused by elevated itraconazole MICs. Early diagnosis and effective treatment for this infection are crucial to prevent disease progression, death, and transmission to other humans and animals.

    Continue Reading

  • Natalie Dormer Joins Netflix Series ‘Extraction’

    Natalie Dormer Joins Netflix Series ‘Extraction’

    Natalie Dormer (The Hunger Games, Game of Thrones) has been cast in the new Netflix series , starring opposite Omar Sy and Boyd Holbrook.

    The show is set in the world of the action thriller movie franchise of the same name, to be helmed by showrunner, writer, and executive producer Glen Mazzara and executive produced by Joe Russo and Anthony Russo’s AGBO.

    In the 8-episode action-packed thriller Extraction, a mercenary (Omar Sy) embarks on a dangerous mission to rescue hostages in Libya. Trapped between warring factions and ruthless killers, he must navigate life-or-death choices while confronting deep emotional wounds. Extraction explores the trauma, betrayal, and moral conflicts of characters pushed to the edge.

    In a series regular role, Dormer will play Clayton Wisper, the leader of a private military contractor, sources tell Deadline.

    This is the second time Netflix has extended a successful original movie franchise into a TV series. It’s To All the Boys I’ve Loved Before film trilogy spawned a hit comedy series, XO, Kitty, which was recently renewed for a third season. In the opposite direction, the streamer has a Peaky Blinders movie coming up based on the popular TV series.

    The 2020 action thriller Extraction, directed by Sam Hargrave, was based on the graphic novel Ciudad by Ande Parks, with art by Fernando León González, and co-written by Joe and Anthony Russo. Chris Hemsworth stars as an Australian black ops mercenary who takes on a mission to save an Indian drug lord’s kidnapped son in Dhaka, Bangladesh, but the mission goes awry when he is double-crossed.

    A sequel, Extraction 2, was released in 2023, with the main cast returning. The movie brings back Hemsworth’s Rake, who is tasked with a new mission — rescuing the battered family of a ruthless Georgian gangster from the prison where they are being held.

    AGBO produced both films.

    In addition to the Russo brothers and Mazzara, executive producers include Angela Russo-Otstot, Scott Nemes, and Chris Castaldi for AGBO, Sam Hargrave, Eric Gitter, and Peter Schwerin, Netflix & AGBO: A Proven Partnership. Ari Costa produces for AGBO.

    Dormer is repped by 111 Media, United Agents, UTA, and Jackoway Austen Tyerman.

    Continue Reading

  • Workers are ‘job hugging’ in a stagnant labor market, but growing resentment means they could bail as soon as the next Great Resignation comes

    Workers are ‘job hugging’ in a stagnant labor market, but growing resentment means they could bail as soon as the next Great Resignation comes

    A stagnating labor market is leading workers to hold tightly onto their jobs, even as growing workplace uncertainty stokes resentment and concern among employees, consultants warn. But while employees are staying put to weather the storm, this act of “job hugging” could only be temporary as they prepare to flee as soon as market conditions improve.

    The pandemic-era “Great Resignation” saw 47 million people quit their jobs in 2021 and 50 million more in 2022 as they looked for flexible working conditions and higher pay. As job openings and turnover returned to pre-Covid levels in 2023, the mass exodus of workers transitioned to the “Great Stay.” 

    Today, as tariff uncertainty threatens companies’ growth plans and private equity funding slows—not to mention advancements in AI stoking employees’ fears about being displaced—workers are staying put with extra anxiety. They’re concerned that should they quit, they wouldn’t be able to find options elsewhere, according to consulting firm Korn Ferry. This act of “job hugging” has workers hanging onto their positions “for dear life.”

    “Given just all the activity that happened post-Covid and then some of these constant layoffs, people are waiting and sitting in seats and hoping that they have more stability,” Korn Ferry managing consultant Stacy DeCesaro told Fortune.

    Since 2024’s fourth quarter, the Eagle Hill Consulting Employee Retention Index has indicated growing employee intent to stay at their current jobs in the next six months. The consultancy also saw a 4.4-point drop in its Market Opportunity Indicator last quarter, indicating a steep decline in employee perceptions of the job market. U.S. payrolls grew by just 73,000 in July, and have expanded by an average of only 35,000 in the last three months.

    “No one is wanting to leave unless they’re very unhappy or miserable in their job or just feel so unsettled by the company,” DeCesaro said.

    Growing employee frustrations

    Just because more employees are sticking around doesn’t mean they are happy about it. A November 2024 report from Glassdoor found that 65% of employees reported feeling “stuck” in their current positions, including 73% of those in tech roles. With fewer alternatives, sitting tight at one’s job has, for many, resulted in cabin fever.

    “It’s no accident that trends like ‘quiet quitting’ are resonating now,” Daniel Zhao, lead economist at Glassdoor, wrote in the report. “As workers feel stuck, pent-up resentment boils under the surface and employee disengagement rises.” 

    On top of bleak job prospects elsewhere, employees are also grappling with a rotating door of company management, which has exacerbated feelings of discomfort and disconnect from a firm’s vision, DeCesaro said. Some of her clients said they’ve worked under three different company presidents in the 18 months. 

    CEO turnover rates have reached their highest in decades, with departures jumping 12% from June 2024 to 2025, according to data from executive placement firm Challenger, Gray & Christmas, reaching the highest levels since the company began tracking turnover in 2002.

    In other cases, DeCesaro said, new management has provided hope for employees, incentivizing them to stick around that much longer, even if their workplace culture ultimately doesn’t end up changing for the better.

    Taken together, these factors have led to the rise of “quiet cracking,” employees reaching a breaking point and mentally checking out. The productivity dip as a result of employee disengagement cost the world economy $438 billion in 2024, according to Gallup’s 2025 State of the Global Workplace report.

    ‘Great Resignation’ redux

    Employees may have few other career options now, but once market conditions approve, this quiet discontent will no doubt mean deja vu for employers, DeCesaro said: another Great Resignation is coming.

    “Once the market improves, I think it’s going to be super active because there’s a lot of pent-up demand of like, ‘I’ve been miserable here for a while, but I’ve just been waiting for a better opportunity or a better market to move,’” DeCesaro said.

    If employers want to ensure their workers don’t leave as soon as they see other career options, they should focus on looking for opportunities to open doors of communication between management and rank-and-file workers, as well as take time to gather and listen to workers’ feedback, according to DeCesaro.

    With some jobs remaining entirely remote, there should be a continued effort to gather once a year or quarter to create a cohesive company culture.

    “It’s going to be a fruit basket turnover of talent,” DeCesaro said. “But if you’ve invested in your people between now and when that happens, people are going to be reticent to leave.”

    Introducing the 2025 Fortune Global 500, the definitive ranking of the biggest companies in the world. Explore this year’s list.

    Continue Reading

  • NordVPN will discontinue Meshnet on December 1

    NordVPN will discontinue Meshnet on December 1

    NordVPN announced today in a that its Meshnet feature will shut down on December 1. All aspects of Meshnet will stop working on that date, though nothing else about NordVPN will be affected. If you were using Meshnet to connect computers, route web traffic through a personal device or share files, you’ll need to find another solution by December.

    As I mentioned in my , Meshnet was one of the most envelope-pushing features on any VPN, letting users link their devices through a NordLynx tunnel without needing to go through a third-party server. Once the tunnel was set up, you could access either device through the other one to share files or access services. With enough connected devices, you could check your work email, visit a friend’s media server, play a remote game on another server and watch your home-based TV subscriptions — all from a single laptop anywhere on the planet. Unbelievably, it was even free to use.

    I’m sad to see Meshnet go, but as NordVPN’s blog post makes clear, it never found its audience. As exciting as it was to people like me who spend all day squinting at the guts of VPNs, it didn’t provide enough everyday value to catch on with the majority of NordVPN’s customers. Hindsight shows us that Meshnet’s benefits, like remote desktop and file sharing, were mainly business-oriented; selling those was always going to be an uphill battle in a market where .

    If you’re one of the few people who was actually using Meshnet, you have a few months to arrange alternatives. Should you want to stay within the NordVPN ecosystem, you can replace its file sharing features with , which gives you 3 GB of storage for free. Of course, Google Drive is also an option. For remote access, NordVPN recommends , a platform where you can connect up to 10 devices without paying.

    Continue Reading

  • First clinical results demonstrate efficacy of VOY-101, a novel gene therapy for GA

    First clinical results demonstrate efficacy of VOY-101, a novel gene therapy for GA

    Clinicians and industry partners continue the race to find the most efficacious therapy for age-related macular degeneration (AMD). A new gene therapy may solve the puzzle for patients with non-neovascular AMD, and more information is coming soon from a Phase 2 trial, according to one retina researcher. Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center in Israel, shared details about VOY-101, a novel, complement-modulating gene therapy for geographic atrophy (GA).

    The Eye Care Network caught up with Dr Trivizki at the American Society of Retina Specialists (ASRS) Annual Meeting in Long Beach, California. He explained the mechanisms beyind VOY-101( Perceive Biotherapeutics, Inc.) and the Phase 1 Beyond study (NCT06087458).

    “In our talk, we showed that VOY-101 is safe and tolerable,” Dr Trivizki recounted. A 12-month survey of 24 enrolled patients showed there was no dose limiting toxicity, no systemic adverse effects and no ocular adverse effects, he said. “There was a really mild, transient intraocular cell effect that we observed during the study, which passed with topical steroids only, and eventually all patients were off steroids with no recurrence,” Dr Trivizki said. “That led us to the conclusion that we can move ahead to the Phase 2 [trial] which…[dosed the first patient in late June].”

    Dr Trivizki went on to explain the mechanism of the treatment, which is designed to provide patients with Complement Factor H gene (CFH) protection. “CFH protection is a protein that was found to protect patients with GA,” Dr Trivizki said. “The idea here is to provide, with one intravitreal injection, the protection effect of CFH…[and] to be able to use the eye as a production for this specific protein, so with a single injection, you can treat the patient for the long term.”

    Dr Trivizki explained that the Phase 1 trial had six sites across three countries, with most of the patients in Tel Aviv. The follow-up, Phase 2 trial, Journey, has started enrollment and dosing, and will follow patients to a 12-month primary endpoint, he added.

    Continue Reading